{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:00:16Z","timestamp":1788325216701,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jaip.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T15:00:50Z","timestamp":1407423650000},"page":"594-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Rituximab and Immune Deficiency: Case Series and Review of the Literature"],"prefix":"10.1016","volume":"2","author":[{"given":"Blanka","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Kopyltsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fung","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bonagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2014.06.003_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.23171","article-title":"The effects of rituximab on immunocompetency in patient with autoimmune disease","volume":"58","author":"Looney","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2014.06.003_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"Van Vollenhoven","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2014.06.003_bib3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"REFLEX Trial, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2014.06.003_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab","volume":"17","author":"David","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib7","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","article-title":"Prolonged hypogammaglobulinemia following rituximab treatment for post transplant EBV associated lymphoproliferative disease","volume":"33","author":"Imashuku","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2014.06.003_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.282","article-title":"Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV related lymphoma","volume":"23","author":"Miles","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib10","first-page":"676","article-title":"Change of serum immunoglobulin levels in patients with diffuse large B-cell lymphoma after rituximab combined with chemotherapy [in Chinese with English abstract]","volume":"3","author":"Wang","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jaip.2014.06.003_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaip.2014.06.003_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","article-title":"Delayed redistribution of CD27, CD40 and CD80 positive B-cells in patient with NHL after rituximab","volume":"137","author":"Nishio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2014.06.003_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: repletion with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jaip.2014.06.003_bib14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2014.06.003_bib15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaip.2014.06.003_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.2009.068940","article-title":"Does rituximab aggravate pre-existing hypogammaglobulinemia?","volume":"63","author":"Diwakar","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jaip.2014.06.003_bib17","doi-asserted-by":"crossref","unstructured":"Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et\u00a0al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 200;94:S1-60.","DOI":"10.1016\/S1081-1206(10)61142-8"},{"key":"10.1016\/j.jaip.2014.06.003_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: defining subgroups in common variable immunodeficiency","volume":"111","author":"Wehr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2014.06.003_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clim.2008.11.008","article-title":"Memory B-cells in healthy and antibody-deficient children","volume":"131","author":"Huck","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2014.06.003_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.06.003_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2003.04274.x","article-title":"Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma","volume":"121","author":"Pettengell","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2014.06.003_bib22","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2014.06.003_bib23","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2014.06.003_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2014.06.003_bib25","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2014.06.003_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2014.06.003_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","article-title":"Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte homeostasis","volume":"91","author":"Irie","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaip.2014.06.003_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B-cell reconstitution after rituximab treatment of lymphoma recapitulates B-cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2014.06.003_bib29","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B-cell populations revealed by B-cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2014.06.003_bib30","first-page":"590","article-title":"Role of maintenance rituximab (Rituxan) therapy in the treatment of follicular lymphoma","volume":"36","author":"Fowler","year":"2011","journal-title":"P\u00a0T"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814002360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814002360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:06:44Z","timestamp":1761973604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219814002360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S2213219814002360"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2014.06.003","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab and Immune Deficiency: Case Series and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}